Indonesia
Tuberculosis profile
| High TB burden | High HIV burden | High MDR-TB burden |
Population  2013 250 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 64 (36–93) 25 (14–37)
Mortality (HIV+TB only) 3.9 (2.2–6.2) 1.6 (0.87–2.5)
Prevalence  (includes HIV+TB) 680 (340–1 100) 272 (138–450)
Incidence  (includes HIV+TB) 460 (410–520) 183 (164–207)
Incidence (HIV+TB only) 15 (8.7–20) 5.8 (3.5–7.8)
Case detection, all forms (%) 71 (63–80)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (1.4–2.5) 12 (8.1–17)
MDR-TB cases among notified pulmonary
TB cases
5 700 (4 200–7 500) 1 100 (770–1 600)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 196 310   6 406
Pulmonary, clinically diagnosed 103 888   1 558
Extrapulmonary 17 420    
       
Total new and relapse 325 582    
Previously treated, excluding relapses 1 521    
Total cases notified 327 103    
Among 325 582 new and relapse cases:
26 054 (8%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 53 (<1%) 3 740 (39%) 3 838
Laboratory-confirmed RR-/MDR-TB cases     912
Patients started on MDR-TB treatment     809
TB/HIV 2013 Number (%)
TB patients with known HIV status 7 631 (2)
HIV-positive TB patients 1 599 (21)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 477 (30)
HIV-positive TB patients on antiretroviral therapy (ART) 332 (21)
HIV-positive people screened for TB 22 190  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 86
Previously treated cases, excluding relapse, registered in 2012 71
HIV-positive TB cases, all types, registered in 2012 49
RR-/MDR-TB cases started on second-line treatment in 2011 60
XDR-TB cases started on second-line treatment in 2011 50
Laboratories 2013  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 0.4
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 23
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 127
% Funded domestically 13%
% Funded internationally 30%
% Unfunded 57%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-04 Data: www.who.int/tb/data